Selected article for: "viral fusion and virus fusion"

Author: Jones, Harrison G.; Battles, Michael B.; Lin, Chun-Chi; Bianchi, Siro; Corti, Davide; McLellan, Jason S.
Title: Alternative conformations of a major antigenic site on RSV F
  • Document date: 2019_7_15
  • ID: 1r20hl2b_4
    Snippet: RSV is an enveloped virus of the Pneumoviridae family and it has a single-stranded, negative-sense RNA genome. There are two subtypes of RSV, A and B, to which many individual strains belong. RSV has two major glycoproteins on the viral surface important for entry: the fusion (F) and attachment (G) glycoproteins [7] . Whereas RSV G is the primary source of sequence variation and defines the subtype of a specific virus, the fusion glycoprotein is .....
    Document: RSV is an enveloped virus of the Pneumoviridae family and it has a single-stranded, negative-sense RNA genome. There are two subtypes of RSV, A and B, to which many individual strains belong. RSV has two major glycoproteins on the viral surface important for entry: the fusion (F) and attachment (G) glycoproteins [7] . Whereas RSV G is the primary source of sequence variation and defines the subtype of a specific virus, the fusion glycoprotein is well conserved with sequence identities >90% [8] . RSV F is a class I fusion glycoprotein initially produced as an inactive precursor, F0, that is subsequently cleaved by furin-like proteases to generate a protomer of disulfide-linked subunits, F1 and F2 [9] [10] [11] [12] . Three of these protomers associate to form the functional trimeric glycoprotein required for membrane fusion and infection [13] [14] [15] . Numerous vaccine trials for RSV are currently underway [16] , many of which contain the RSV F glycoprotein as an antigen because it has been shown that F is a major target of neutralizing antibodies [17, 18] and is the only protein on the viral surface that is strictly required for entry [19, 20] .

    Search related documents:
    Co phrase search for related documents
    • neutralize antibody and viral surface: 1, 2
    • neutralize antibody and viral surface protein: 1
    • primary source and viral surface: 1
    • RSV vaccine trial and specific virus: 1
    • RSV vaccine trial and vaccine trial: 1, 2
    • sequence identity and single strand: 1
    • sequence identity and specific virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • sequence identity and viral surface: 1, 2, 3, 4
    • sequence identity and viral surface protein: 1
    • sequence variation and single strand: 1
    • sequence variation and specific virus: 1
    • sequence variation and viral surface: 1, 2, 3
    • single strand and specific virus: 1, 2, 3
    • single strand and viral surface: 1
    • specific virus and vaccine trial: 1, 2, 3, 4, 5
    • specific virus and viral surface: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • specific virus and viral surface protein: 1, 2, 3, 4, 5, 6, 7